Immunovant (IMVT) reported a fiscal Q2 net loss Thursday of $0.74 per diluted share, widening from a loss of $0.45 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.60.
The clinical-stage immunology company didn't report any revenue for the quarter ended Sept. 30, as expected by analysts surveyed by Capital IQ.
The company's shares were up more than 1% in recent premarket activity.
Price: 29.10, Change: -0.29, Percent Change: -0.99
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。